Scientific deep-dive

Who Loses More Weight on a GLP-1?

Across 64 randomized trials, the only subgroup difference was sex: women lost 10.9% against 6.8% for men. Age, race, ethnicity, starting BMI and starting HbA1c made no significant difference.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

“Will it work for someone like me?” is the question underneath most of what people read about these drugs. A systematic review pooled 64 randomized trials to answer it, and found essentially one difference: women lost more than men. Age, race, ethnicity, starting BMI and starting blood sugar made no significant difference.[1]

What differed, and what did not

Across six trials covering 19,906 patients analyzed by sex, weight loss was 10.9% among women (95% CI 7.0 to 14.8) against 6.8% among men (95% CI 4.6 to 9.0).[1]

Subgroups examined for differences in treatment effect. From a review of 41 articles representing 64 randomized trials.
SubgroupTrials analyzableDifference found
Sex6 (19,906 patients)Yes — 10.9% vs 6.8%
Age7 (4,314)None significant
Race9 (25,229)None significant
Ethnicity7 (8,328)None significant
Baseline BMI15 (9,473)None significant
Baseline HbA1c4 (1,886)None significant

Why the empty column is the useful one

Most coverage of these drugs is built on the assumption that response varies enormously and that the trick is finding your personal angle. This review suggests the opposite: the drug behaves about the same across the characteristics people most often worry about. A separate tirzepatide analysis found the same for obesity that began before age 25, which responded much like obesity that began later.

Across 15 trials and 9,473 patients, starting BMI made no significant difference to how much weight was lost.

One caveat arrived after this was written. A large real-world cohort did find outcomes differing by race and ethnicity, which we take apart in who responds in the real world. In short, trials equalize cost, supply and dose escalation, and ordinary care does not, so the gap lies in the conditions rather than in the patients. Keep that in mind before you pay for a program built around personalization, along with a second point: a group average cannot tell you what one person will lose. Consistency across subgroups is not the same as consistency between people, and individual variation within every one of those groups remains large.

How much weight the nulls can carry

Less than the headline implies, and the review is transparent about it. Look at the middle column of that table again: the HbA1c conclusion rests on four trials and 1,886 patients. That is a weak basis for “no difference”, and it is not the same as evidence that no difference exists.

  • Absence of a detected difference is not proof of sameness, especially in the smaller analyses.
  • Subgroup analysis is exploratory by nature even when pre-specified, because trials are powered for their main outcome and not for slices of it.
  • Reporting was uneven. Baseline BMI was examined in 75% of the trials, sex in only 21%, so the subgroups that matter most to individual readers are the least studied.

About the sex difference specifically

The difference is real in this analysis, and it is easy to over-interpret. Percentage weight loss is not a pure measure of drug response. Women on average weigh less than men, so the same absolute loss registers as a larger percentage. Differences in body composition and in dosing relative to body size also feed into that gap.

What the trials show is that women lost a larger share of their body weight, and the reasons are not established. That does not show the drug works better in women in any mechanistic sense, and nobody should choose or avoid treatment on the basis of it. Women also report more nausea and hair loss; the side-effect numbers by sex are in GLP-1 side effects in women vs men. When it comes to choosing a seller, our semaglutide boards for women and for men print this split beside the ranking.

Frequently Asked Questions

Across 64 randomized trials, the only subgroup difference detected was by sex: women lost 10.9% of body weight against 6.8% for men. No significant differences appeared by age, race, ethnicity, starting BMI or starting HbA1c.
Not on this evidence. Fifteen trials covering 9,473 patients found no significant difference in treatment effect by baseline BMI, measured as kilograms lost.
The reasons are not established, and percentage weight loss is not a pure measure of drug response. Women on average weigh less than men, so an equal absolute loss registers as a larger percentage. Body composition and dosing relative to body size also contribute.
No significant difference was found across seven trials covering 4,314 patients. That is a relatively small evidence base for a conclusion of no difference, so it is better read as an absence of any signal than as proof that age is irrelevant.
Consistency across subgroups is not the same as consistency between individuals. Variation within every one of these groups remains large, and a group mean cannot tell you what will happen to any one person.

References

  1. 1.Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis JAMA Internal Medicine. 2026. PMID: 41770554.

Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

8 min read

How Long Is the Evidence, Actually?

These are indefinite treatments. In the largest randomized trial at the weight indication, the mean time on the drug was 34.2 months. What the long trials ran for, and what a short evidence base does and does not mean.

7 min read

GLP-1 Drugs and Headache: A Side Effect, and a Treatment

Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.

7 min read

Semaglutide for Alcohol Use Disorder: Read the Placebo Arm

Heavy drinking days fell 41.1 points on semaglutide and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.

6 min read

GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested

The largest randomized trial found a GLP-1 added nothing to quit rates (63% against 65% on placebo) while holding post-cessation weight for as long as it was taken. A year later that advantage had gone too.

7 min read

Best Injection for Weight Loss? Every Approved Shot, Ranked on Trial Data

Zepbound took off the most weight of any injection FDA has approved for weight, and beat semaglutide head to head. Wegovy has the proven cardiovascular benefit. Label and trial data on weight, side effects and dropouts, plus what is not approved yet.

8 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.1

Direct Meds

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →